Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.

Published on Apr 1, 2020in JAMA Oncology24.799
· DOI :10.1001/JAMAONCOL.2019.6486
Fausto Petrelli45
Estimated H-index: 45
,
Roberto Labianca76
Estimated H-index: 76
+ 20 AuthorsAlberto Sobrero62
Estimated H-index: 62
Sources
Abstract
Importance The addition of oxaliplatin to the standard 6-month fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer has been reported to reduce the risk of relapse although it does not increase survival. The Three or Six Colon Adjuvant (TOSCA) trial compared 3 months with 6 months of adjuvant fluoropyrimidine and oxaliplatin-based chemotherapy in patients with stage III colon cancer. The utility remains unknown. Objective To assess the noninferiority and toxic effects of 3 vs 6 months of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine plus oxaliplatin) adjunct chemotherapy among patients with high-risk stage II resected colorectal cancer enrolled in the TOSCA trial. Design, Setting, and Participants The TOSCA study was a noninferiority phase 3 randomized clinical trial conducted from June 2007 to March 2013 in 130 Italian centers. Included patients had resected colorectal cancer located 12 cm from the anal verge by endoscopy or above the peritoneal reflection at surgery. In this preplanned study assessing the per-protocol population, 5-year relapse-free survival was evaluated in 1254 patients with high-risk stage II resected colorectal cancer who had received adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine plus oxaliplatin). Interventions Patients were originally randomized (1:1) in the TOSCA trial to receive 3 months (experimental group) or 6 months (control) of standard doses of FOLFOX or CAPOX at the discretion of the treating physician. Main Outcome and Measures A hazard ratio of at least 1.2 between the 3-month and 6-month chemotherapy groups was set to reject the null hypothesis of noninferiority. Results Overall, 1254 patients (mean [SD] age, 62.4 [9.8] years; 565 women [45.1%]) with clinical high-risk stage II resected colorectal cancer were analyzed at a median follow-up of 62 months (interquartile range, 53-71) months. Of them, 301 patients (24.0%) had pT4N0M0 tumors, and the remaining 953 patients (76.0%) had high-risk pT3N0M0 tumors; 776 patients (61.9%) received FOLFOX and 478 (38.1%) received CAPOX. The 5-year relapse-free survival was 82.2% for the 3-month arm and 88.2% for the 6-month arm, with an estimated hazard ratio of 1.41 (95% CI, 1.05-1.89;P = .86 for noninferiority). For CAPOX, the 5-year relapse-free survival was similar in the 2 arms (difference, 0.76% favoring the 6-month arm; 95% CI, −6.28% to 7.80%), whereas for FOLFOX, the difference was pronounced: 8.56% in favor of the longer-duration arm (95% CI, 3.45%-13.67%). Nevertheless, the test for an interaction between duration and regimen was not statistically significant. Neurotoxicity was approximately 5 times lower in the shorter duration arm than in the longer duration arm. Conclusions and Relevance In the 3-month arm, the treatment was significantly less toxic than in the 6-month arm. Noninferiority was not shown for 5-year relapse-free survival. However, a possible regimen effect was observed, suggesting that either 3 months of CAPOX or 6 months of FOLFOX therapy can be used whenever an oxaliplatin doublet is indicated for treatment of patients with stage II colorectal cancer. Trial Registration ClinicalTrials.gov Identifier:NCT0064660
References14
Newest
#1E. Gabriela Chiorean (Fred Hutchinson Cancer Research Center)H-Index: 21
#2Govind Nandakumar (Cornell University)H-Index: 12
Last. Manish A. Shah (Cornell University)H-Index: 72
view all 16 authors...
PURPOSETo provide resource-stratified, evidence-based recommendations on the treatment and follow-up of patients with early-stage colorectal cancer.METHODSASCO convened a multidisciplinary, multinational Expert Panel that reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus process with additional experts for one round of formal ratings.RESULTSExisting sets of guidelines from 12 guideline developers were identified and reviewed; adapted recommendations from...
50 CitationsSource
#1Alberto Sobrero (UniSR: Vita-Salute San Raffaele University)H-Index: 62
#2Sara Lonardi (Mario Negri Institute for Pharmacological Research)H-Index: 52
Last. Roberto Labianca (UniSR: Vita-Salute San Raffaele University)H-Index: 76
view all 21 authors...
PurposeGiven the cumulative neurotoxicity associated with oxaliplatin, a shorter duration of adjuvant therapy, if equally efficacious, would be advantageous for patients and health-care systems.MethodsThe Three or Six Colon Adjuvant trial is an open-label, phase III, multicenter, noninferiority trial randomizing patients with high-risk stage II or stage III colon cancer to receive 3 months or 6 months of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine plus oxaliplatin)....
38 CitationsSource
#1Axel Grothey (Mayo Clinic)H-Index: 86
#2Alberto SobreroH-Index: 62
Last. Timothy Iveson (University Hospital Southampton NHS Foundation Trust)H-Index: 35
view all 23 authors...
Abstract Background Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures. Methods We performed a prospective, preplanned, pooled analysis of six randomized, phase 3 trials that were conducted concurrently to evaluate the noninferiority o...
334 CitationsSource
#1Kamila Naxerova (Harvard University)H-Index: 20
#2Johannes G. Reiter (Harvard University)H-Index: 17
Last. Rakesh K. Jain (Harvard University)H-Index: 210
view all 12 authors...
The spread of cancer cells from primary tumors to regional lymph nodes is often associated with reduced survival. One prevailing model to explain this association posits that fatal, distant metastases are seeded by lymph node metastases. This view provides a mechanistic basis for the TNM staging system and is the rationale for surgical resection of tumor-draining lymph nodes. Here we examine the evolutionary relationship between primary tumor, lymph node, and distant metastases in human colorect...
206 CitationsSource
#1Joseph Kannarkatt (MSU: Michigan State University)H-Index: 3
#2Joe Joseph (St. George's University)H-Index: 1
Last. Borys HrinczenkoH-Index: 5
view all 5 authors...
The decision to treat a patient with stage II colon cancer with adjuvant chemotherapy can be challenging. Although the benefit of treatment is clear in most patients with stage III disease, the decision to provide chemotherapy after surgical resection in stage II disease must be made on an individual basis. Several trials have demonstrated the small but absolute benefits of receiving adjuvant chemotherapy for stage II colon cancer for disease-free survival and overall survival. In an attempt to ...
70 CitationsSource
#1Sara LonardiH-Index: 52
#2Alberto SobreroH-Index: 62
Last. R. LabiancaH-Index: 22
view all 21 authors...
Six months of oxaliplatin-based adjuvant chemotherapy is standard of care for radically resected stage III colon cancer and an accepted option for high-risk stage II. A shorter duration of therapy, if equally efficacious, would be advantageous for patients and Health-Care Systems.TOSCA ['Randomized trial investigating the role of FOLFOX-4 or XELOX (3 versus 6 months) regimen duration and bevacizumab as adjuvant therapy for patients with stage II/III colon cancer] is an open-label, phase III, mul...
30 CitationsSource
#1Manish A. Shah (UF: University of Florida)H-Index: 72
#1Manish A. Shah (UF: University of Florida)H-Index: 1
Last. Daniel J. Sargent (UF: University of Florida)H-Index: 3
view all 10 authors...
PurposeFluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. The impact of oxaliplatin added to FU + LV on the time course of recurrence and survival remains unknown.Patients and MethodsA total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant Treatment of Colon Cancer), and XELOXA (Adjuvant XELOX) were...
76 CitationsSource
#1Quyen D. Chu (LSU Health Sciences Center Shreveport)H-Index: 22
#2Meijiao Zhou (LSU Health Sciences Center New Orleans)H-Index: 5
Last. Xiao-Cheng Wu (LSU Health Sciences Center New Orleans)H-Index: 4
view all 6 authors...
Background A survival paradox between Stage IIB/C and Stage IIIA colon cancers exists. It is unclear how adequate lymph nodes dissection (LN) and post-surgery chemotherapy contribute to the survival paradox. We intended to assess the impact of these two factors on the survival paradox.
22 CitationsSource
#1Thierry AndréH-Index: 80
#2Armand de Gramont (UNIL: University of Lausanne)H-Index: 18
Last. Aimery de GramontH-Index: 56
view all 25 authors...
Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods Survival actualization after 10-year follow-up was performed in 2,246 patients with resected st...
296 CitationsSource
#1Min Jung KimH-Index: 13
#1Min Jung KimH-Index: 15
Last. Jae-Gahb Park (SNU: Seoul National University)H-Index: 70
view all 11 authors...
Background The survival paradox between stage IIB/C (T4N0) and stage IIIA (T1-2N1) colon cancer remains in the 7th edition of the American Joint Committee on Cancer staging system. This multicenter study aimed to compare the oncologic outcomes of T4N0 and T1-2N1 colon cancers and to investigate the presumptive prognostic factors that might influence the survival paradox.
40 CitationsSource
Cited By12
Newest
#6Qi Li (SHU: Shanghai University)
#6Qi Li (SHU: Shanghai University)H-Index: 64
Background: Tumor stroma percentage (TSP), as an independent, low-cost prognostic factor, could complement current pathology and act as a more feasible risk factor for prognosis. The objective of this study was to investigate the prognostic significance of TSP in a robust rapid multi-dynamic approach with the application of MATLAB and threshold Algorithm for Gray Image analysis. Methods: Using a retrospective collection of 1539 colorectal cancer patients comprising three independent cohorts; one...
Source
#1Eiji Oki (Kyushu University)H-Index: 57
#2Jun Watanabe (Yokohama City University Medical Center)H-Index: 15
Last. T. YoshinoH-Index: 6
view all 16 authors...
BACKGROUND Recent advances in adjuvant chemotherapy for early colon cancer have widened physicians' recommendations on the regimen and duration (3 or 6 months) of the treatment. We conducted this prospective study to evaluate whether the 12-gene recurrence score (12-RS) assay affected physicians' recommendations on adjuvant treatment selection. PATIENTS AND METHODS Patients with stage IIIA/IIIB or stage II colon cancer were enrolled. After the patients discussed adjuvant treatment with their tre...
1 CitationsSource
#1Michael Webster-Clark (UNC: University of North Carolina at Chapel Hill)H-Index: 4
#2Alexander P. Keil (UNC: University of North Carolina at Chapel Hill)H-Index: 13
Last. Jennifer L. Lund (UNC: University of North Carolina at Chapel Hill)H-Index: 24
view all 6 authors...
Adjuvant chemotherapy regimens take months to complete. Despite this, studies evaluate chemotherapy adherence via measures assessed at the end of treatment (e.g. number of patients missing any dose, relative dose intensity [RDI]). This approach ignores information like the timing of treatment delays. We propose longitudinal cumulative dose (LCD) to integrate impacts of dose reductions, missed doses, and dose delays over time. We obtained data from the 2,246 participants in the MOSAIC trial rando...
Source
#2Sandor SchokkerH-Index: 6
view all 20 authors...
We assessed the feasibility of adjuvant S-1 and oxaliplatin following neoadjuvant chemoradiotherapy (nCRT) and esophagectomy. Patients treated with nCRT (paclitaxel, carboplatin) and esophagectomy received six 21-day cycles with oxaliplatin (130 mg/m2) on day 1 and S-1 (25 mg/m2 twice daily) on days 1–14. The primary endpoint was feasibility, defined as ≥50% completing treatment. We performed exploratory propensity-score matching to compare survival, ERCC1 and Thymidylate Synthase (TS) immunohis...
Source
#1Goro Nakayama (Nagoya University)H-Index: 24
#2Nao TakanoH-Index: 7
Last. Yasuhiro Kodera (Nagoya University)H-Index: 81
view all 30 authors...
Abstract Background Peripheral sensory neuropathy (PSN) caused by oxaliplatin-based adjuvant chemotherapy adversely affects patients' quality of life. This study evaluated the efficacy and safety of capecitabine plus oxaliplatin (CAPOX) with intermittent oxaliplatin use compared with the standard CAPOX in adjuvant therapy for colon cancer. Patients and methods Patients with curative resection for stage II/III colon cancer were randomly assigned to receive either CAPOX with continuous oxaliplatin...
Source
#1Sara Elena RebuzziH-Index: 8
#2Guido PesolaH-Index: 1
Last. Alberto SobreroH-Index: 62
view all 4 authors...
In stage II colon cancer management, surgery alone has shown a high cure rate (about 80%), and the role of adjuvant chemotherapy is still a matter of debate. Patients with high-risk features (T4, insufficient nodal sampling, grading, etc.) have a poorer prognosis and, usually, adjuvant chemotherapy is recommended. The purpose of the present study is to highlight and discuss what is still unclear and not completely defined from the previous trials regarding risk stratification and therapeutic ben...
1 CitationsSource
Adjuvant chemotherapy for colon cancer (UICC stage II and III) has been under investigation over the last 30 years, regarding treatment duration and regimens. In this review, choice of regimen, its duration, possible limitations and future perspectives are discussed. Monotherapy with 5-fluorouracil was followed by addition of oxaliplatin, resulting in improved 3-yr disease free survival (DFS) and overall survival (OS) rates, but also increased peripheral sensory neurotoxicity (PSN). The Internat...
1 CitationsSource
#1Andreas Teufel (Heidelberg University)H-Index: 30
#2Michael Gerken (University of Regensburg)H-Index: 16
Last. Monika Klinkhammer-Schalke (University of Regensburg)H-Index: 20
view all 6 authors...
Abstract Background The benefit of adjuvant chemotherapy in Union for International Cancer Control (UICC) stage III colon cancer has been demonstrated in numerous studies. While adjuvant chemotherapy is generally not recommended in stage II patients, its role in high-risk UICC stage II disease (e.g. T4 tumours) remains controversial. Methods The present population-based multicenter cohort study investigated the influence of adjuvant chemotherapy on survival and recurrence rates in high-risk UICC...
1 CitationsSource
#1Jiaxin ZhangH-Index: 1
#2Guang Chen (Beijing University of Chinese Medicine)H-Index: 70
Last. Yong’an Ye (Beijing University of Chinese Medicine)H-Index: 6
view all 11 authors...
It is the great priority to detect colorectal cancer (CRC) as early as possible, finally to reduce the incidence and mortality of CRC. However, although colonoscopy is recommended in many consensuses, yet no one systematic review is conducted to figure out how colonoscopy could change the incidence and mortality. In our study, we conducted a comprehensive meta-analysis to evaluate the association between colonoscopy screening and the incidence or mortality of CRC. PubMed, EMBASE, and PMC databas...
1 CitationsSource
#1Zachary R. McCaw (Google)H-Index: 7
#2Dae Hyun KimH-Index: 32
Last. Lee-Jen Wei (Harvard University)H-Index: 43
view all 3 authors...
1 CitationsSource